Skip directly to content

TAGline 2014

NEWS ON THE FIGHT TO END HIV/AIDS, VIRAL HEPATITIS, AND TUBERCULOSIS

TAGline Fall 2014: hello generics

  • A Drug by Any Other Name
    The basics of generic medications, bioequivalence, and the push for good manufacturing practices

    By Tim Horn
     
  • The Road to Treatment Access
    Generic drug registration, licensing, and a trip to Gilead’s islands
    By Karyn Kaplan and Tracy Swan
     
  • Safeguarding against Stock-Outs
    The time has come for U.S. tuberculosis programs to have full access to the Stop TB Partnership’s Global Drug Facility procurement and stockpile safety nets
    By Kenyon Farrow
     
  • Generics vs. the Giant
    For people with drug-resistant tuberculosis (DR-TB), generic linezolid may be a lifesaver. But only if quality-assured versions are available and affordable
    By Erica Lessem


TAGline Spring 2014: The April Fool's Issue

  • Fool Us Once…
    By Tim Horn
    We’re being duped by our government agencies. We’re being hoodwinked by the Affordable Care Act (ACA). We’re being bamboozled by pharmaceutical companies and research networks. In this April Fools’ issue of TAGline, we highlight several missteps in research and policy that have required some degree of advocacy to remedy and ensure that the jokes don’t remain on us.
     
  • Forgotten Negatives: The Limits of Treatment as Prevention
    The CDC’s High-Impact Prevention strategy takes aim at the stubborn HIV incidence rate in the United States. The only problem: it doesn’t include an ambitious plan for those at risk for the virus
    By Jeremiah Johnson
     
  • The White House’s Fuzzy Math
    An Office of National AIDS Policy progress report obscures the state of the domestic U.S. HIV/AIDS response

    By Mark Harrington
     
  • Marketplace Menaces: Discriminatory Practices by the ACA’s Qualified Health Plans
    Advocates scramble to stay ahead of coverage rejections, formulary concerns, and exorbitant out-of-pocket expenses facing people living with HIV

    By Kenyon Farrow
     
  • Better Late Than Never: Efavirenz Dose Optimization
    After a study suggests that we’ve been using too high a dose of efavirenz for a decade and a half, the move toward scaling up a lower and more cost-effective one faces some hurdles

    By Tim Horn and Polly Clayden
     
  • Punked by Pharma: Public Funds for Private Products
    Tax dollars are making it easier for the drug and diagnostics industry to develop and market essential TB products. Is the public getting a fair return on its investment?

    By Lindsay McKenna
     
  • Fool’s Errand: The Sloppy Science of the MDR-TB STREAM Trial
    Confirming the efficacy and safety of bedaquiline-inclusive regimens is a priority. Comparing them to unvalidated MDR-TB drug combinations in the planned STREAM study is not the way to go about it

    By Mike Frick